The founders of Fulcrum Therapeutics bring together world-class expertise and unparalleled achievements in gene regulation, genetics, cell biology and screening and computation in the pursuit of innovative new therapies.

In addition to having a passion for research, each scientific founder is also passionate about harnessing his or her research to transform the treatment of disease.


Bradley E. Bernstein, M.D., Ph.D.

Professor, Department of Pathology, Massachusetts General Hospital and Harvard Medical School; Broad Institute Member

Bradley Bernstein received his B.S. in physics from Yale University and his M.D. and Ph.D. from the University of Washington School of Medicine. He completed a residency in clinical pathology at Brigham and Women’s Hospital, and carried out postdoctoral research at Harvard University with Stuart Schreiber. He joined the faculty of Massachusetts General Hospital and Harvard Medical School in 2005. His research focuses on epigenetics — changes in gene activity governed by influences outside the genes themselves. His work is notable for the discovery of epigenetic mechanisms in stem cells and the annotation of thousands of enhancer ‘switches’ in the human genome relevant to common disease. He co-directs the Epigenomics Program at the Broad Institute of MIT and Harvard and oversees a production center for the NHGRI-sponsored ENCODE project, which seeks to catalog all of the working parts of the genome. His honors and awards include the Paul Marks Prize for Cancer Research, a Research Professorship from the American Cancer Society, an Early Career Scientist award from the Howard Hughes Medical Institute, a Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund, a Junior Faculty Award from the Culpeper Foundation and election into the American Society for Clinical Investigation.

 

Michael R. Green, M.D., Ph.D.

Chair and Professor, University of Massachusetts Medical School, Department of Molecular, Cell and Cancer Biology; Director of the UMass Medical School Cancer Center; Investigator of the Howard Hughes Medical Institute

Michael Green received his M.D. and Ph.D. from Washington University School of Medicine in 1981. He carried out postdoctoral work at Harvard University, where he joined as a faculty member in 1984. In 1990, he joined the Program in Molecular Medicine at the University of Massachusetts Medical School, and served as the director of the Program of Gene Function and Expression from 1999 to 2014. He has made pioneering contributions to the understanding of the mechanisms that regulate gene expression in eukaryotes and how alterations in gene expression contribute to cancer and other human diseases. Recently he has used transcription-based approaches and functional screens to identify new genes and regulatory pathways involved in epigenetic regulation and cancer, which have important therapeutic implications. As a young investigator he was the recipient of the Presidential Young Investigators Award (1985), the Searle Scholar Award (1986), the McKnight Neuroscience Award (1991) and was a Harvey Lecturer (1993). He is an elected member of the National Academy of Sciences (2014), National Academy of Medicine (2015) and the European Molecular Biology Organization (2010).

 

Rudolf Jaenisch, M.D.

Professor of Biology, MIT; Founding Member, Whitehead Institute for Biomedical Research

Rudolf Jaenisch earned his M.D. from the University of Munich in 1967. After conducting postdoctoral work in bacteriophages at the Max Planck Institute in Munich, he held research positions at Princeton University, the Fox Chase Institute for Cancer Research and the Salk Institute. From 1977 to 1984 he was the head of the Department of Tumor Biology at the Heinrich Pette Institute at the University of Hamburg. He joined MIT in 1984. His central research interest is to understand epigenetic regulation of gene expression in mammalian development and disease. He is a pioneer in the understanding of how to transdifferentiate cells from one type to another. His work with embryonic stem cells is providing fundamental discoveries for the field of regenerative medicine. His numerous awards and honors include the Genetics Prize from the Gruber Foundation (2001), election to the National Academy of Sciences (2003), the Max Delbruck Medal (2006), the National Medal of Science (2010), the Wolf Prize in Medicine (2011) and the Otto Warburg Medal (2014).

 

Jeannie T. Lee, M.D., Ph.D.

Professor of Genetics (and Pathology), Harvard Medical School; Molecular Biologist, Massachusetts General Hospital; Co-Director, Harvard Epigenetics Initiative; Investigator of the Howard Hughes Medical Institute

Jeannie Lee received her B.A. in biochemistry and molecular biology from Harvard University and her M.D. and Ph.D. degrees from the University of Pennsylvania School of Medicine, with postgraduate training at the Whitehead Institute/MIT and Massachusetts General Hospital. She is a pioneer in the field of epigenetic regulation by long noncoding RNAs (lncRNA) and is known for her work on Xist, Tsix RNA and X-inactivation, as well as for establishing a link between lncRNA and chromatin complexes. Her honors and awards include the Lurie Prize from the Foundation for the NIH (2016); election to the National Academy of Science (2015); the Distinguished Graduate Award of the University of Pennsylvania School of Medicine (2014); the NIH MERIT Award (2011); the Molecular Biology Prize from the National Academy of Sciences (2010); appointment as a Fellow of the AAAS (2010); the Pew Scholars Award (2000); and the Basil O’Connor Scholar Award (1998). She was also chief resident of clinical pathology at the MGH (1994). She has served on the Board of Directors of the Genetics Society of America and currently serves on the Board of Overseers for the Boston Philharmonic Orchestras.

 

Danny Reinberg, Ph.D.

Terry and Mel Karmazin Professor of Biochemistry and Molecular Pharmacology; Department of Biochemistry and Molecular Pharmacology New York University School of Medicine; Investigator of the Howard Hughes Medical Institute

Danny Reinberg received his B.S. in biochemistry from Catholic University in Valparaiso, Chile and a Ph.D. in molecular biology from the Albert Einstein College of Medicine. He is a world-recognized leader in the fields of mammalian transcriptional regulation, chromatin dynamics and epigenetic regulation. His numerous advances are detailed in over 180 publications and his key contributions include identifying the structural and functional characterization of critical components of the human gene expression machinery; discovering several chromatin remodeling factors and key insights into the mechanisms by which genes are activated and repressed in the context of chromatin; and purifying and characterizing several histone methyltransferases and chromatin modifying complexes that have shed great insight into the regulatory interplay between histone modification and gene expression. He is an elected member of the National Academy of Medicine (2013) and the National Academy of Sciences (2015).